Mela Sciences (MELA) has lost almost half its market cap this morning, after an FDA staff report says Mela's skin cancer device "may do more harm than good." The device faces the FDA's advisory panel on Thursday. Shares -47% to $3.37.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs